Bausch Health

BHC

Market cap $2.58B

Overview Fund Activity

6.97 USD

-0.21

2.92%

At close Updated Sep 16, 1:31 PM EDT

1 day

-2.92%

5 days

-3.06%

1 month

-13.09%

3 months

17.94%

6 months

-0.99%

Year to date

-12.22%

1 year

-0.43%

5 years

-58.71%

10 years

-97.01%

About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Employees: 20,700

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more funds holding in top 10

Funds holding in top 10: 5 [Q1] → 7 (+2) [Q2]

2% more capital invested

Capital invested by funds: $1.58B [Q1] → $1.62B (+$38.8M) [Q2]

0.65% less ownership

Funds ownership: 66.26% [Q1] → 65.61% (-0.65%) [Q2]

3% less repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 62

8% less funds holding

Funds holding: 226 [Q1] → 208 (-18) [Q2]

37% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 43

73% less call options, than puts

Call options by funds: $14.4M | Put options by funds: $53.4M

See Fund Rankings

Financial journalist opinion

Based on 10 articles about BHC published over the past 30 days

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Bausch Health remains a Buy as the market overstates debt and patent risks, while the business shows stable cash generation and operational momentum. Q2 results confirmed growth in core segments, improved profitability, and management's commitment to debt reduction and strategic portfolio development. Despite a heavy debt load, refinancing progress and upgraded 2025 guidance support my thesis of undervaluation and a 27% upside to $9.1 per share.

Bausch Health: Repricing Continues As Deleveraging Gains Traction

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, and CUPERTINO, Calif. , Sept. 11, 2025 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation ("DURECT").

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development, to Bausch Health's hepatology pipeline LAVAL, QC, AND CUPERTINO, CA / ACCESS Newswire / September 11, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), a global, diversified pharmaceutical company, today announced the successful completion of its previously announced tender offer to acquire DURECT Corporation ("DURECT"). Under the terms of the agreement, Bausch Health acquired all outstanding shares of DURECT for $1.75 per share in cash, representing a total upfront cash payment of approximately $63 million at closing.

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient-reported outcomes following implantation of enVista Envy and the enVista® monofocal IOL in cataract s.

Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophthalmology has published results from an investigator-initiated study which evaluated the effectiveness of XIIDRA (lifitegrast ophthalmic solution) 5% in alleviating end-of-day (EOD) eye dryness and discomfort in symptomatic contact lens (CL) wearers.* XIIDRA is a prescription eye drop used to treat.

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, today announced that the Company's proven Thermage technology has successfully been used to perform more than 5 million skin tightening and smoothing treatments. Thermage utilizes monopolar radiofrequency energy that can safely heat layers of skin and stimulate collagen production, naturally.

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

Zacks Investment Research

Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Bausch (BHC) Up 21.4% Since Last Earnings Report: Can It Continue?

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) today announced that BHC Lyon Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Bausch Health Americas, Inc. ("BHA"), and an indirect subsidiary of Bausch Health Companies Inc. ("BHC"), has extended the expiration date of its tender offer (the "Offer") to acquire all of the outstanding shares of common stock of DURECT Corporation for $1.75 per share in an all-cash transaction for an upfront consideration of approximately $63 million at closing, with the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subject to certain adjustments in respect of a retention plan) if the milestones are achieved before the earlier of the 10 year anniversary of the first commercial sale of larsucosterol (5-cholesten-3ß, 25-diol 3-sulfate sodium salt) in the United States and December 31, 2045. The Offer, which was previously scheduled to expire at 5:00 p.m.

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Quebec and Saskatchewan. This new public drug plan availability of CABTREO is in addition to that announced last month for those using the Ontario and Nova Scotia public drug plans as well as through the federal government's Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations as well as those of the Correctional Service of Canada (CSC) and Veterans Affairs Canada.

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

Bausch + Lomb board members resign after Icahn agreement ends

Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

Bausch + Lomb board members resign after Icahn agreement ends

See News Rankings

Charts implemented using Lightweight Charts™